A new glucocerebrosidase chaperone reduces α-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with gaucher disease and parkinsonism [PDF]
et al, +3 more
core +1 more source
Crossing the barrier: nanomedicine as a frontier therapy for neuropathic Gaucher disease type 3. [PDF]
Saif M +4 more
europepmc +1 more source
Pathological Protein Targets in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapies. [PDF]
Dzamko N.
europepmc +1 more source
Underlying Mechanisms of GBA1 in Parkinson's Disease and Dementia with Lewy Bodies: Narrative Review. [PDF]
Bougea A.
europepmc +1 more source
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher disease. [PDF]
Camou F +24 more
europepmc +1 more source
Quantitative and Comparative Assessment of Recombinant Human β-Glucocerebrosidase Uptake Bioactivity Using a Stable hMMR-Expressing CHO Cell Model. [PDF]
Wang L, Xu K, Lyu P, Hu X, Li J.
europepmc +1 more source
Urine bis(Monoacylglycerol)Phosphate and risk of freezing of gait in parkinson's disease. [PDF]
Sang S, Yang N.
europepmc +1 more source
Case Report: Progressive myoclonus epilepsy as an early manifestation of neuronopathic Gaucher disease. [PDF]
Fang Z +5 more
europepmc +1 more source
HEPES in Cell Culture Alters the Multi-Omics Profile Exhibited by Gaucher Disease Fibroblasts. [PDF]
Corazolla EM +14 more
europepmc +1 more source
Unveiling an Uncommon Glucosylceramidase (GBA) Mutation: Gaucher Disease Due to p.Ser276Phe Substitution. [PDF]
Kumar N +4 more
europepmc +1 more source

